Cost-Utility of Sunitinib (SU) for Treatment of Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in Scotland and Wales

#538

Introduction: SU is an oral multitargeted tyrosine kinase inhibitor approved in Europe for advanced/metastatic well-differentiated pNET.

Aim(s): This study evaluated the cost-utility of SU + best supportive care (BSC) compared with placebo + BSC for health technology assessment submissions to Scotland and Wales (Jan and Mar 2011).

Materials and methods: A Markov model was developed to estimate quality-adjusted life-years (QALYs) and costs (£) of pNET treatment over lifetime, with three health states included: progression-free, post-progression and death. Transition probabilities (calculated using parametric survival modeling) and adverse event rates were based on the phase III pNET trial of SU, with extension-phase data included for overall survival (OS). BSC OS was adjusted for crossover with a rank-preserving structural failure time (RPSFT) model. Sensitivity analyses examined alternate survival assumptions and OS hazard ratios. Resource use was estimated by two UK pNET experts. A UK NHS perspective was adopted with 3.5% discounting.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Johns A, Eatock M, Johal S,

Keywords: Sunitinib, overall survival, cost-utility, pancreatic NET,